Epigenomics

#Advertorial #Epigenomics #Genomics #Mutliomics #Neurological disease #Sampled

From genomics to multiomics: A broader view of neurological disease

In this paid-for advertorial for the Fall 2026 issue of DDW, Sampled shares insight on neurological disease with a genomics and multiomics lens.  Genomic testing can identify drivers of neurological disease, but many variants remain difficult to interpret. Multiomics helps to close this gap by connecting genetic findings with… Read More

#Exclusive Content

#Epigenomics #Financing #Fundraising #Tune Therapeutics

Tune raises $175m to support epigenome editing programmes

Epigenome editing company Tune Therapeutics has announced the completion of over $175 million in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution Foundation.  Tune Co-Founder Dr Charles Gersbach, whose research at Duke University formed the basis for Tune’s TEMPO epi-editing platform, commented: “Tune has… Read More

#Business & Investment #News

Human liver
#American Association for the Study of Liver Diseases (AASLD) #DNA #Epigenomics #HBV #Liver disease #Tune Therapeutics #Viral hepatitis

Preclinical data suggests functional cure for HBV

Epigenome editing company Tune Therapeutics has showcased new data at the American Association for the Study of Liver Diseases (AASLD) conference, in support of its drive to develop a lasting, functional cure for chronic Hepatitis B Virus (HBV). Tune presented its lead HBV programme at the 2023 iteration of the… Read More

#News

DNA research molecule
#CAR-T #DNA #Epigenomics #Genetic editing #Genomics #Immunology #Oncology #Tune Therapeutic

Moving the needle of CAR-T beyond oncology 

CAR-T Therapies have revolutionised the field of personalised medicine, especially in oncology. DDW’s Megan Thomas speaks with Dr Blythe Sather, Vice President and Head of Research at Tune Therapeutics, about how genetic tuning will transform the reach for CAR-T therapies, the different diseases that can benefit, and the disruptive technology… Read More

#Cancer Research #Exclusive Content